Long-term phase of schizophrenia: impact of atypical agents.
Standard
Long-term phase of schizophrenia: impact of atypical agents. / Naber, Dieter.
in: INT CLIN PSYCHOPHARM, Jahrgang 15, Nr. 4, 4, 2000, S. 11-14.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term phase of schizophrenia: impact of atypical agents.
AU - Naber, Dieter
PY - 2000
Y1 - 2000
N2 - Typical antipsychotic agents are poorly suited to the long-term treatment of schizophrenia, particularly since the introduction of atypical compounds has increased the expectations of both physicians and patients. Well-being and quality of life--now important considerations--have shown significant improvements in patients treated with atypical agents such as amisulpride rather than typical agents such as haloperidol. This is associated with alleviation of negative symptoms and cognitive deficits, benefits which are not seen with traditional agents and which increase the likelihood of successful rehabilitation.
AB - Typical antipsychotic agents are poorly suited to the long-term treatment of schizophrenia, particularly since the introduction of atypical compounds has increased the expectations of both physicians and patients. Well-being and quality of life--now important considerations--have shown significant improvements in patients treated with atypical agents such as amisulpride rather than typical agents such as haloperidol. This is associated with alleviation of negative symptoms and cognitive deficits, benefits which are not seen with traditional agents and which increase the likelihood of successful rehabilitation.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 11
EP - 14
JO - INT CLIN PSYCHOPHARM
JF - INT CLIN PSYCHOPHARM
SN - 0268-1315
IS - 4
M1 - 4
ER -
